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Abstract 
Atrial fibrillation (AF), as it represents the most common sustained cardiac arrhythmia, affects 1%–2% of 
the general population and up to 15% of people over 80 years.  High blood pressure, due to its high 
prevalence in the general population, is by far the most common condition associated with AF, although a 
variety of diseases, including valvular, coronary heart and metabolic diseases, are held to create the 
substrate favouring AF.  Due to the concomitance of these conditions, it is quite often challenging to 
dissect the precise role of high blood pressure in triggering/causing AF.   
Hence, even though the intimate association between high blood pressure and AF has been known for 
decades, the underlying mechanisms remain partially unknown.  Accumulating evidences point to a major 
role of the renin-angiotensin-aldosterone system in inducing cardiac inflammation and fibrosis, and 
therefore electric and structural left atrial and ventricular remodelling, with changes in ions and cell 
junctions leading to AF development.  These evidences are herein reviewed with a particular emphasis to 
the role of the renin-angiotensin-system aldosterone system. 
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Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with an estimated prevalence of 
1%–2% in the general population and up to 15% of people over 80 years [1-5].  These rates likely entail a 
marked underestimation because AF can be totally asymptomatic (silent AF).  Moreover, due to aging of 
the population, a doubling of the prevalence of AF is expected to occur in the next 50 years thus leading 
an epidemic of AF worldwide. 
AF doubles the risk of death independently of other known predictors of mortality [6] and represents the 
major cause of cardio-embolic stroke with ensuing long-term disability [1].  It also worsens the quality of 
life [7,8] and can lead to cognitive dysfunction and dementia by causing silent and recurring strokes [9]. 
As AF mandates long-term treatment for heart rate control and anticoagulation and, moreover, accounts 
for one third of all hospitalizations for arrhythmias, it imposes an enormous burden on the community [1]. 
Due to the high prevalence of high blood pressure (HBP) in the general population the vast majority of the 
cases of AF occurs in hypertensive patients, even though many other factors, as valvular and coronary 
artery diseases, heart failure, metabolic disorders as hyperthyroidism, obesity, and diabetes mellitus, 
often concur to create the stage favouring and maintaining AF.  As HBP involves multiple hormonal and 
biochemical changes, it has been challenging to disentangle the role of HBP in triggering/causing AF from 
that of these other factors, and therefore the relative weight of different putative mechanisms underlying 
the association between AF and HBP still remain poorly understood [10].  Nonetheless, there is little 
doubt that a better identification of the mechanisms and predictors of AF in HBP is key for developing 
more effective prevention strategies and intervention programs.  The aim of this review is meant to 
provide updated information on prevalence, predictors, and putative mechanisms of AF in the 
hypertensive heart disease. 
1. Incidence of AF in HT patients.  After anecdotal reports of an association between AF and HBP [11], 
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unambiguous evidence that HBP contributes to AF came from the Framingham Heart Study in 1994 [12].  
During 38 years of follow-up of 2,090 men and 2,641 women 562 new cases of AF were observed, with a 
doubling AF incidence after 50 years of age with each successive decade, leading to almost 10% rate of AF 
in people who reached age 80 years of age. 
The age-dependency of AF was emphasized by a more recent analysis of a cohort of the Framingham 
Heart Study: this showed increased age-adjusted AF prevalence rates from 1958-1967 to 1998-2007, 
which can be explained by the improved medical care leading to increased survival in general and after 
the onset of AF [13].  Of note, in the most recently examined decade of the Framingham Study, i.e. 1998–
2007, notwithstanding the reduction over time of the prevalence of most modifiable risk factors for AF 
[13], HBP and anti-hypertensive treatment carried the greatest population-attributable risk.  After age-
adjustment, the only predictors of AF were HBP and ECG evidence of hypertensive left ventricular (LVH), 
besides diabetes mellitus and cigarette smoking (in women).  Moreover, hypertensive men and women 
had 80% and 70% greater risk for AF, respectively, than normotensive subjects; ECG evidence of LVH 
increased risk of AF by almost a 3- and 4-fold, respectively (Table I)[12]. 
Other studies thereafter confirmed the role of HBP in causing AF: for example, in the 30,424 high CV risk 
participants of the Ontarget study (mean age 66 years), who were in sinus rhythm at enrolment, new AF 
occurred in 6.8% of the patients during a median follow-up period of 4.7 years.  Age, history of HBP, and 
coronary or cerebrovascular disease, systolic BP, pulse pressure, LVH, body mass index, and serum 
creatinine predicted incident AF [14], which, in turn, implied an increased risk of congestive heart failure 
and cardiovascular death.  In the PIUMA Study that prospectively examined the determinants of AF in 
2,482 untreated essential hypertensive patients without valvular or rhythm diseases at baseline, LVMI 
predicted new onset AF and, alongside left atrial diameter, also chronic AF [15].  BP, EKG evidence of LVH, 
age, and male gender predicted AF in the hypertensive patients with echocardiographically determined 
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LVH of the LIFE study [16]; moreover, regression of LVH with treatment was associated with a lower 
incidence of AF as compared to persistent LVH [17;18], thus confirming the causative role of HBP-induced 
LVH in triggering AF.  More recent studies showed that the increased risk of AF in hypertensive patients is 
not confined to those at high CV risk, like the ONTARGET or LIFE Studies patients, but would be shared 
also by those with BP in the upper normal range [19,20].  Of note, the observation that night-time 
ambulatory BP correlated with the left atrial size and the plasma levels of natriuretic peptides even in 
normotensive subjects with AF supported the causative role of BP in AF [21]. 
Finally, in summarizing the studies reporting an association of AF with HBP the 2012 Position paper of the 
Working Group on ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension 
(ESH)[22] overall indicated that from 49% to 90% of AF patients have HBP [23-27]. 
2. Pathophysiology of AF associated with HT 
The major mechanisms underlying AF in HT, although often concomitant, are herein reviewed separately 
for the sake of clarity.  
2.1 Genetic factors. Rare gene mutations predisposing to AF were identified, but they were limited to 
isolated families without traditional risk factors; their interaction with HBP can be only speculated at this 
time [28,29].  In 2003 Chen et al. described a gain-of-function mutation in KCNQ1 gene responsible for AF 
in a Chinese family [30].  This gene encodes the α subunit of the slow component of the delayed rectifier 
K+ current (IKs).  The variant, as well as others thereafter identified, increases IKs during the action 
potential (AP) in the atria, thus shortening the atrial AP duration and/or atrial refractoriness [31,32].  Gain 
of function mutations in other K+ channels (KCNE2, KCNE5 or KCNJ2), and loss-of-function mutation in the 
KCNA5 gene, which codes the atrial-specific K+ voltage gated channel Kv1.5, were also reported to 
promote AF by inducing early atrial repolarisation [33-37].  Increased susceptibility to AF was also found in 
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patients with mutations in Na+ or Ca2+ channel genes that control ion currents across cell or sarcoplasmic 
membranes in atrial myocytes [38-40].  Evidence that some mutations specifically increase the 
susceptibility to AF in hypertensive cardiac disease is, however, lacking.  It is however, conceivable that, in 
the carriers of gene variants predisposing to HBP and AF, an interaction with additional risk factors, 
particularly in the presence of hypertensive cardiac remodelling, can more easily lead to AF with aging (Fig. 
1)[41,42]. 
2.2 Channels and cell junctions. Mechanic overload, due to HBP or ischemic injury, were found to induce 
an abnormal expression of ion channels and/or junctional complexes, as connexin 40 and connexin 43, 
which can enhance myocardium vulnerability by triggering focal ectopic and re-entry activity [43,44].  
Whether these alterations play a major role in AF in hypertensive patients has not been specifically 
investigated and, therefore, is unknown.  Undoubtedly, HBP, by causing LVH and impaired LV filling, 
stretches the atria, thus favouring AF [45].  Moreover, in patients with HBP atrial remodelling and fibrosis 
can in turn affect channels and/or junctions in atrial cardiomyocytes [43]. 
2.3 Renin-angiotensin-aldosterone system (RAAS).  Activation of RAAS, not only is a feature of high renin 
essential hypertension, renovascular hypertension and renin secreting tumours, but also represents a 
common consequence of treatment with diuretics and direct vasodilatators.  It has electrophysiological 
effects that can trigger arrhythmias and ultimately induce structural remodelling of the atria, favouring 
the onset and the perpetuation of AF.  For example, angiotensin (Ang) II activates profibrotic pathways via 
AT1 receptor in myofibroblasts [16,29], thus promoting transformation of resident atrial fibroblasts into 
myofibroblasts, as well as synthesis of TGF1, a major profibrotic cytokine in the atria and the ventricles.  
Myofibroblasts may in turn release TGF1, and other paracrine factors as PDGF, connective tissue growth 
factor (CTGF), fibroblast growth factor (FGF)-2, and interleukines of the IL-6 family that also affect 
myocyte electrical function [46,47].  Of note, TGF1 released by myofibroblasts differentially regulates the 
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transcription and function of the Na+ channels [47], while CTGF affects the connexin expression pattern, 
leading to atrial remodelling and fibrosis (Fig. 2)[46].  Accordingly, some studies reported a lower incident 
AF in hypertensive patients treated with RAS inhibitors compared to controls [16,48]. 
Even though atrial wall stretch would be expected to lower aldosterone via enhanced ANP release, plasma 
aldosterone was found to be elevated in AF patients; conversely, restoration of sinus rhythm lowered its 
levels [49].  Interestingly, a causative role of aldosterone in the development of AF is supported by the 
finding of a 12-fold increase of the risk of AF in a large retrospective study of patients with primary 
aldosteronism, as compared to matched essential hypertensive patients (OR 12, 95% CI: 3.2-45.2, p 
<.0001)[50].  This increased risk of AF could be due to several mechanisms favouring left atrium dilatation, 
collagen deposition and development of cardiac fibrosis, including hypokalaemia, aldosterone-induced LV 
remodelling, hypertrophy, and diastolic dysfunction [51,52].  Aldosterone-induced oxidative stress and 
inflammation could further favour atrial structural and electrical remodelling [53,54].  The 
aforementioned reduced incidence of AF with AT1 receptor blockers (ARBs) in the LIFE and VALUE studies, 
compared to atenolol or amlodipine, respectively [16,48], also indirectly support a role of 
hyperaldosteronism in the onset of AF as ARBs may confer a protective effect not only by antagonizing 
Ang II on the AT1 receptors, but also by blunting AT1-mediated Ang II-dependent aldosterone secretion. 
3. Diagnostic approach and treatment of AF in the hypertensive patient.  Despite the well-known role of 
both HBP and AF as major causes of stroke, both conditions as well as their association remain markedly 
under-diagnosed.  The Screening for Atrial Fibrillation in the Elderly (SAFE) Study showed that many UK 
primary care providers were unable to diagnose AF with EKG, with overlooking of as many as 20% of the 
cases [55].  This has ominous consequences, as undiagnosed AF patients cannot receive anti-coagulation 
and therefore are exposed to the risk of stroke.  In 2012 acknowledging this burden and the under-
diagnosis of AF in hypertensive patients, the Working Group on ‘Hypertension arrhythmias and 
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thrombosis’ of the European Society of Hypertension (ESH) published a position paper on the diagnostic 
approach, prevention and treatment of HBP associated with AF [22].  The recommendation of performing 
an EKG whenever AF is suspected and to perform 24-hours EKG Holter monitoring, or external event 
recorders for longer periods, when EKG does not show AF, but silent AF is probable, were reinforced.  
According to the AHA/ACC 2014 AF Guidelines all hypertensive patients with AF should also have a 
transthoracic echocardiogram to detect underlying structural disease, assess cardiac function, and 
measure atrial size [56]. 
In the ARAPACIS study (Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: 
Collaborative Italian Study) a 52% prevalence of echocardiographic LVH was found in patients with non 
valvular AF.  Compared to those without LVH, the LVH patients were older and had a higher prevalence of 
HBP, besides diabetes, previous myocardial infarction and arterial wall stiffening, as evidenced by an 
ankle-brachial index > 0.90 [57]. 
New devices have been developed to automatically detect silent AF, including the MyDiagnostick 
(https://www.mydiagnostick.com)[58,59] and the MicrolifeWatchBP Home A (http://www.microlife.com), 
an oscillometric blood pressure monitor with an embedded algorithm that automatically detects pulse 
irregularity, and advices the user to transmit his/her pulse data to the general practitioner.  The National 
Institute for Health and Care Excellence (NICE) supports the WatchBP device to detect asymptomatic AF 
and reduce the incidence of thromboembolic stroke (https://www.nice.org.uk). 
4. Hypertension and thrombo-embolic risk stratification.  Alongside a history of stroke or transient 
ischemic attack, increasing age, and structural heart disease (LVH or LV dysfunction), HBP entails an 
established predictor of stroke in patients with AF.  The CHA2DS2 VASC score (http://www.mdcalc.com) 
has become the most popular tool in clinical practice to determine the cardioembolic risk in non valvular 
AF [60].  The HAS-BLED score (http://www.mdcalc.com) was also introduced in clinical practice to 
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estimate the risk of bleeding with anticoagulation and therefore to assist physician in the challenging task 
to decide whether to anticoagulate or not.  Of importance, HBP enters in the calculation of both the 
CHA2DS2 VASC and the HAS-BLED score, but the BP threshold at which the benefit of stroke prevention 
with anticoagulation exceeds the risk of cerebral haemorrhage is unknown.  Thus, even though a strict 
control of BP is recommended before starting the anticoagulant treatment, the level of BP associated with 
the minimal risk of stroke is unknown.  
5. Rate and sinus rhythm control.  Besides prevention of cardioembolism, goals of AF management 
include rate control, and restoration and maintenance of sinus rhythm.  Rate control impacts on the 
quality of life, reduces morbidity, and decreases the potential for developing tachycardia-induced 
cardiomyopathy.   The choice among beta blockers, non-dihydropyridine calcium channel blockers, 
digoxin, and antiarrhythmic drugs as sotalol, strictly depends on the patient’s symptoms, hemodynamic 
status, presence/absence of heart failure, and potential triggers of AF [56]. 
In randomized clinical trials (RCTs) long-term AF management to restore and maintain sinus rhythm failed 
to show superiority over rhythm control in terms of death-free survival [23,43,61].  However, when 
applied to patients who are candidates to either rhythm or rate control strategy, the former resulted in 
more hospitalizations [62], suggesting that it is not the optimal choice for each patient.  Whether control 
of BP affects duration of sinus rhythm maintenance or rate control remains to be established. 
6. Treatment of hypertension and prevention of AF.  The tight relationship between HBP and AF found in 
clinical studies [1,13,16] would imply that a good control of BP prevents atrial fibrillation. In the 
aforementioned LIFE study, the hypertensive patients who achieved in-treatment systolic BP lower than 
130 mmHg showed a reduced risk of new-onset AF as compared to those who remained with systolic BP > 
142 mmHg [18].  Moreover, an effective antihypertensive therapy was associated with reduction of stroke 
rates, irrespectively of the drugs employed [63,64].  Nevertheless, BP remained remarkably unappreciated 
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in AF trials notwithstanding the fact that the prevalence of HT ranged from 79% (RE-LY) to 90% 
(ROCKET)(for a review see Ref [22]).   The RE-LY, ROCKET, ARISTOTLE, AVERROES and ENGAGE AF TIMI 48 
Studies, which examined the effectiveness of the oral non vitamin K anticoagulants (NVKACs) dabigatran, 
rivaroxaban, apixaban, and edoxaban in stroke prevention in AF, provided only limited data on BP values 
and BP control during the study, and on concomitant antihypertensive medication.  A post-hoc analysis of 
data from AF trials considering the BP-adjusted outcomes could provide more accurate information on the 
effectiveness of NVKACs in preventing stroke or systemic embolism [22]. 
Theoretically, by preventing diastolic dysfunction and, thereby atrial stretch and dilation, all 
antihypertensive agents might be effective in reducing the risk of incident AF.  However, no RCTs 
comparing head-to-head different agents have been performed specifically to this aim.  Some studies 
suggest that RAS inhibitors can be more efficacious than other agents in preventing AF [16]: by meta-
analysing 11 studies entailing a total of 56,308 patients Healey et al. found that ACE-I and ARBs overall 
reduced the relative risk of AF by 28% (95% CI: 15%-40%, p=.0002), without significant differences 
between these classes [29].  However, in this meta-analysis only three studies, which entailed 26,403 
patients, were hypertension trials [16,65].  When only these trials were examined the relative risk 
reduction furnished by RAS blockade was two-fold smaller (12% (p= .04), possibly reflecting the smaller 
benefits of the RAS inhibitors when an effective antihypertensive therapy was used in the control arm. 
Moreover, these hypertension trials were heterogeneous for inclusion criteria, with Captopril prevention 
Project (CAPP) and Swedish Trial in Old Patients with Hypertension-2 (STOP-H2) enrolling hypertensive 
patients from the general population [65,66], and the LIFE Study recruiting high-risk patients with left 
ventricular hypertrophy [16].  Of interest, only the LIFE Study reported a reduction in AF with losartan 
over atenolol, whilst CAPP and STOP-H-2 showed no advantages.  These results overall indicate that 
prevention of AF is more effective in the hypertensive patients with most severe hemodynamic 
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abnormalities. 
Another meta-analysis also showed AF prevention of the hypertensive patients with ACEI or ARBs [67], 
while two others failed to show superiority of ACEI or ARBs over active therapy of the control groups 
[68,69].  Hence, it is not possible at present to draw solid conclusions about the superiority of the RAAS 
blockade over not RAAS blocker-based antihypertensive treatment (Table II).  Nonetheless, some issues 
deserve consideration: 1) incident AF could have been under-detected in the oldest trials CAPP and STOP-
2H as it was not a pre-specified endpoint; 2) patients included in the HOPE and TRASCEND study were 
high cardiovascular risk patients with HBP being only one of their risk factors. Therefore, these trials are 
not comparable to the trials including 'pure' hypertensive patients; 3) the follow-up largely differed across 
trials; 4) only in the LIFE and VALUE studies, which showed the beneficial effects of ARBs on AF prevention, 
EKG was recorded yearly.  Overall, these results suggested that AF could have been missed in many 
studies and that a proper search for AF is key for ascertainment of the antihypertensive effect of drug. 
Finally, since AF develops more frequently in the hypertrophied dysfunctional hearts of patients with 
severe or resistant HBP, whether novel strategies such as baroreceptor stimulation therapy (BAT) and 
renal sympathetic denervation can be helpful for AF prevention and/or regression remains to be 
investigated.  
7. Conclusions 
In summary, since AF is common in the adult population and even more so in patients with HBP, in which 
it worsen prognosis and quality of life, there is an urgent need for a better understanding of its underlying 
mechanisms. As in many other fields of Medicine, better knowledge will translate into more effective 
prevention and treatment strategies of this arrhythmia that imposes an enormous burden on public 
health and will do even more so in the next decades. 
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Table I.  Risk factors for the development of AF in 38-years follow-up of the Framingham Study. 
 Age-adjusted OR Multiple risk Factor-adjusted OR 
Risk Factors Men Women Men Women 
Smoking 1.0 1.4* 1.1 1.4 
Diabetes 1.7** 2.1*** 1.4* 1.6** 
EKG-LVH 3.0*** 3.8*** 1.4 1.3 
HT 1.8*** 1.7*** 1.5** 1.4* 
BMI 1.03 1.02 -- -- 
Alcohol 1.01 0.95 -- -- 
BMI: body mass index; EKG–LVH: echocardiographic left ventricular hypertrophy; OR: odds 
ratio. 
Analysis performed using 2-year pooled logistic regression; *p <.05; **p <.01; ***p <0.001.  
Mod. From Kannel W.B. [12] 
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Table II.  Randomized clinical trials on the effects of ACE-inhibitors or ARBs in HT patients with AF and inclusion in the meta-analyses. 
Author 
Study acronym, 
year 
Pure HT 
study 
(yes/no) 
Additional 
Inclusion criteria 
Population 
(n) 
Follow-
up (mo) 
Active group 
treatment 
ACEI/ARB 
Control 
group 
treatment 
Meta-analysis inclusion 
(yes/no) 
 
 
     
Healey, 
2005 
Anand, 
2006 
Schneider, 
2010 
Huang,  
2011 
Hansson, 
CAPP, 1999 [65] 
 
yes  10,915 73 Captopril 
Diuretic  
-blocker 
yes yes yes yes 
Hansson, 
STOP-H2, 1999 
[66] 
 
yes  6,303 60 Enalapril/Lisinopril 
Diuretic  
-blocker CCB 
yes yes yes yes 
Wachtell, 
LIFE, 2005 [16] 
 
yes LVH 8,480 57 Losartan Atenolol yes yes yes yes 
Schmieder, 
VALUE, 2008 
[48] 
 
no HIgh CV risk 13,760 50 Valsartan Amlodipine no yes yes yes 
Salehlan, 
HOPE, 2007 [70] 
 
no HIgh CV risk 8,335 54 Ramipril Placebo no no yes no 
Yusuf, 
TRASCEND, 
2008 [71] 
no HIgh CV risk 5,701 56 Telmisartan Placebo no no yes no 
Fogari, 2006 
[72] 
no Paroxysmal AF 222 12 
Losartan + 
Amiodarone 
Amlodipine + 
Amiodarone 
no no no yes 
Fogari, 2008 
[73] 
no AF 369 12 Ramipril Valsartan Amlodipine no no no yes 
Abbreviations. AF: atrial fibrillation; ARB: Angiotensin AT1 receptors blockers; CCB: calcium channel blockers; CV: cardiovascular; HT: arterial hypertension; mo: months. 
Pure HT study indicates that HT was the only inclusion criteria. 
‘Additional inclusion criteria’ indicates that, besides HT, the inclusion criteria entailed high cardiovascular risk (coronary, peripheral, or cerebrovascular disease, or diabetes 
with end-organ damage) or AF.
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Legends to Figures 
Figure 1. Factors predisposing to atrial fibrillation (AF).  A: AF prevalence increases with aging in 
the general population. B: In the normotensive subjects atrial vulnerability is mostly caused by 
genetic (yellow) and age-related remodelling (purple). Both factors contribute to onset of AF, 
which first presents as paroxysmal, then permanent, and finally as persistent (petrol blue). C. 
Remodelling induced by high blood pressure is the major factor predisposing to AF in the 
hypertensive patients, leading to an anticipation of the age of onset of paroxysmal AF and to a 
swifter transition to permanent AF.  (Modified from Wolf P.A. [1 ]and Hejiman J. [41]). 
Figure 2. Mechanisms underlying the development of atrial fibrillation (AF) in hypertensive 
patients.  Left ventricular hypertrophy (LVH), by inducing electrical and structural remodelling 
not only of the ventricular, but also of the left atrial chamber, is the major determinant of AF 
onset.  Activation of the sympathetic and renin-angiotensin systems contributes lo LVH mostly 
through inflammation and fibrosis. Aldosterone, the final effector of the RAAS, potently concurs 
to fibrosis and LVH development. The genetic background, by inducing changes in ion channels 
or cellular junctions and therefore leading to electrical and/or structural abnormalities, crucially 
affects the predisposition not only to AF but also to hypertension.  
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